SCHEMBL2537526

SCHEMBL2537526

O=C(O)CCc1cc(-c2ccc(OC(F)(F)F)cc2)ccc1OCc1ccc(-c2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 9/20 0.58
FFAR4 Q5NUL3 7/20 0.58
PTGER4 P35408 3/20 0.54
PTGER3 P43115 3/20 0.54
AKR1B1 P15121 1/20 0.52
S1PR1 P21453 1/20 0.52
PTGER1 P34995 2/20 0.50
PTGER2 P43116 2/20 0.50
PPARD Q03181 1/20 0.48
MME P08473 1/20 0.46
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
SLC13A5 Q86YT5 1/20 0.45
PLA2G4A P47712 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2532590 1.00 FFAR1 (0.58) FFAR1FFAR4PTGER4PTGER3AKR1B1
SCHEMBL2534776 0.97 FFAR1 (0.56) FFAR1FFAR4PTGER4PTGER3AKR1B1
SCHEMBL2538764 0.97 FFAR1 (0.55) FFAR1FFAR4PTGER4PTGER3AKR1B1
SCHEMBL2539633 0.93 FFAR4 (0.52) FFAR1FFAR4PTGER4PTGER3S1PR1
SCHEMBL2533757 0.92 PPARD (0.55) FFAR1FFAR4S1PR1PPARD
SCHEMBL2536628 0.92 FFAR1 (0.53) FFAR1FFAR4PTGER4PTGER3PTGER1
SCHEMBL2536454 0.92 FFAR1 (0.52) FFAR1FFAR4PTGER4PTGER3PTGER1
SCHEMBL2538768 0.92 FFAR4 (0.51) FFAR1FFAR4PTGER4PTGER3S1PR1
SCHEMBL2536390 0.90 FFAR4 (0.49) FFAR1FFAR4PTGER4PTGER3PTGER1
SCHEMBL2535066 0.90 FFAR4 (0.49) FFAR1FFAR4PTGER4PTGER3PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044236-B2 Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-10-25 US disclosed
EP-2080751-A1 CARBOXYLIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-07-22 EP disclosed
US-20080275116-A1 Carboxilic acid derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275116-A1 Carboxilic acid derivatives SERPINE1, CTRL, SERPINC1 FFAR1 710/4885FFAR4 2537/4885PTGER4 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.